Compare Match Group Inc (MTCH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Match Group Inc trades at $41.46 (market cap $9.45B), while State Street SPDR S&P Biotech ETF trades at $159.93. The key difference: Match Group Inc pays a 1.94% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| MTCH | XBI | |
|---|---|---|
Market Cap | $9.45B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $42.44 | $169.55 |
52-Week Low | $28.90 | $93.43 |
Enterprise Value | $12.41B | — |
Dividend Yield | 1.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $41.15, down 1.7% today, near the analyst low target of $41.00. The stock shows a bullish technical trend with recent earnings beating expectations in Q2 2026. Fundamentals are solid with a P/E of 14.59, net income margin of 20.17%, and strong cash flow growth. Recent news highlights AI-driven product innovations at Tinder and institutional buying interest.
Outlook is positive with a consensus price target of $42.50, offering modest upside. Key opportunities include AI integration and user growth, while risks involve high debt levels and competitive pressures in the dating app market. The stock presents a balanced risk-reward profile for growth-oriented investors.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
